Horizon Therapeutics - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating thyroid eye disease, according to a statement.

Amgen’s thyroid eye disease medicine gets EU market authorisation

HQ Team April 27, 2025: The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating.

by HealthQuill
April 27, 2025
0 Comments

Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two drugs that treat rare inflammatory diseases.

Drugs Health Pharma

Amgen completes $27.8b acquisition of Horizon Therapeutics

Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two.